



#9

Attorney Docket No. VPI/00-114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : J. Golec
Application No.: 09/863,649
Group Art Unit : 1646
Examiner : Not Yet Assigned
Filed : May 23, 2001
For : CASPASE INHIBITORS AND USES THEREOF

Cambridge, Massachusetts
December 13, 2002

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231
Attention: RO/US

TRANSMITTAL LETTER FOR RESPONSE TO NOTICE TO COMPLY


This is in response to an October 15, 2002 Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures ("Notice") in the above-identified application.

The Notice indicates that the "application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825" for omitting a nucleotide and/or amino acid sequence listing ("sequence listing"). The Notice requires applicant

to provide a computer readable form of a sequence listing, a paper copy of the listing, and an Amendment requesting entry of the listing into the application. The Notice also requires applicant to provide a statement that the content of the computer readable form is identical to the written form of the sequence listing and that the listing includes no new matter.

Accordingly, applicant transmits herewith a diskette containing the sequence listing in a computer readable form, a paper copy of the sequence listing, an Amendment, and the required statements.

Respectfully submitted,



Lisa A. Dixon
Attorney for Applicant
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617) 444-6396
Facsimile: (617) 444-6483



Docket No.: VPI/00-114 US

Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 019 224 190 US

Date of Deposit: December 13, 2002

I hereby certify that the following documents:

1. Preliminary Amendment (3 pages, with Exhibit 1);
2. Transmittal Letter for Response to Notice to Comply (with copy of Notice to Comply);
3. Statement in Support of Computer Readable Form Submission Under 37 CFR §1.821(9f);
4. Copy of Sequence listing and Sequence Listing Diskette; and
5. this return postcard receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington D.C. 20231

Karen DiRocco

(type or printed name of person mailing document(s))

Karen DiRocco

(signature of person mailing document(s))



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/863,649	05/23/2001	Julian M.C. Golec	VPI/00-114 US

27916
VERTEX PHARMACEUTICALS INC.
130 WAVERLY STREET
CAMBRIDGE, MA 02139-4242



CONFIRMATION NO. 1044
FORMALITIES LETTER



OC000000008952892

Date Mailed: 10/15/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Ryan

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE